Yesterday, the FDA announced the approval of Amgen’s Avsola (infliximab-axxq). This is the fourth biosimilar approved by the FDA for the immunosuppressive drug from Janssen, Remicade (infliximab). Avsola IV was approved for treatment of Crohn’s disease, pediatric Crohn’s disease, ulcerative colitis, rheumatoid arthritis and psoriatic arthritis, but will require a warning for patients to discontinue use if a serious infection develops.
